Do you think coverage will start to evolve to include comprehensive NGS for all metastatic disease? Is there a substantial cost difference between limited panels and NGS? Seems more efficient to grab everything all at once…if possible! #TumorBoardTuesday
#tumorboardtuesday
#TumorBoardTuesday